Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men |
| |
| Authors: | Ligia A Pinto Timothy J Wilkin Troy J Kemp Martha Abrahamsen Kimberly Isaacs-Soriano Yuanji Pan Jennifer Webster-Cyriaque Joel M Palefsky Anna R Giuliano |
| |
| Institution: | 1. HPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States;2. Weill Cornell Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, United States;3. Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States;4. University of North Carolina, Chapel Hill, NC, United States;5. University of California, San Francisco, CA, United States |
| |
| Abstract: | Duration and functional aspects of the oral and systemic antibody responses following HPV vaccination in HIV-negative (HIV?) and HIV-positive (HIV+) men are not well characterized. Oral and systemic HPV-16 and HPV-18-specific antibody levels were evaluated over 18-months of follow-up, in HIV+ and HIV? men. Sera and oral gargles from 147 HIV? men, ages 27–45 and 75 HIV+ men, ages 22–61, who received 3-doses of quadrivalent HPV vaccine were tested for HPV-16 and HPV-18 antibodies at Day 1, Month 7 (1?month post-dose 3), and Month 18 (12?months post-dose 3) and HPV avidity (Day 1, and Month 7) using L1-VLP ELISA.All individuals seroconverted, regardless of HIV-status, following 3-doses of vaccine for HPV-16 and HPV-18. Serum HPV-16 and HPV-18 antibody geometric mean levels were >2-fold lower in HIV+ compared to HIV? men at Month 7 (HPV-16: 808.5 versus 2119.8?EU/mL, and HPV-18: 285.8 versus 611.6?EU/mL, p?<?0.001) but not significantly different at Month 18 (HPV-16: 281.8 versus 359.7?EU/mL, p?=?0.145, and HPV-18: 120.2 versus 93.4?EU/mL, p?=?0.372). Post-vaccination, only oral HPV-16 antibody levels at Month 7 were significantly different between HIV+ and HIV? men (127.7 versus 177.1?EU/mg of IgG, p?=?0.008). Among baseline HPV-seronegative men, circulating levels of HPV-16 and HPV-18 antibodies were up to >3 fold lower in HIV+ men, at Months 7 and 18. In contrast, levels of HPV-16 and HPV-18 antibodies after vaccination were not inferior in baseline HPV-seropositive, HIV+ men. HPV-16 and HPV-18 avidity was lower among HIV+ compared to HIV? men at Month 7 (HPV-16: 1.95?M versus 2.12?M, p?=?0.027; HPV-18: 1.50?M versus 1.72?M, p?<?0.001).Although differences in peak antibody levels were observed between HIV+ and HIV? men following 3 doses of vaccine, plateau antibody levels were overall comparable, and avidity was relatively high for both groups. These data indicate that the vaccine induced antibody affinity maturation in both HIV+ and HIV? men and will likely result in long-term protective immune responses. |
| |
| Keywords: | HPV HIV Oral antibodies HPV vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
